|
NitrosAMIDES - Should they be treated the same as Nitrosamines?
|
|
3
|
948
|
May 7, 2025
|
|
Understanding Aqueous Nitrosation Kinetics of 4-Substituted Piperidines To Risk Assess Pharmaceutical Processes and Products-Pub
|
|
1
|
141
|
May 6, 2025
|
|
How to set Acceptance criteria for nitrosamines impurities in FDC-FPPs
|
|
1
|
144
|
May 6, 2025
|
|
N-nitroso-Impurity C in Metamizol Drug product
|
|
16
|
1905
|
May 6, 2025
|
|
Phenyl Morpholine
|
|
4
|
225
|
May 6, 2025
|
|
Nitrosamine internal standards - what should be taken into consideration?
|
|
5
|
283
|
May 6, 2025
|
|
Interferencia de matriz para cuantificación de NDBA
|
|
0
|
66
|
May 5, 2025
|
|
📅 Updates on Approaches to Acceptable Intakes of Nitrosamine Drug Substance Related Impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products(CRCG)
|
|
39
|
3332
|
May 2, 2025
|
|
MDD for Metformin
|
|
4
|
234
|
May 2, 2025
|
|
:australia: TGA - Latest Update to Nitrosamine Limits
|
|
8
|
1736
|
May 2, 2025
|
|
Nitrosourea, aromatic n-nitroso copmounds
|
|
2
|
198
|
May 2, 2025
|
|
US FDA- Generic Drug Science and Research Priority Initiatives for Fiscal Year (FY) 2024
|
|
1
|
497
|
May 1, 2025
|
|
🇰🇷 Korea NRA on 'Case Studies on Reducing Impurities in Pharmaceuticals (focusing on NDMA)"
|
|
0
|
295
|
May 1, 2025
|
|
Autonomous CPCA Web-based calculator FREE
|
|
33
|
6013
|
April 30, 2025
|
|
Risk Assessment ASS/Paracetamol/Coffein tablets
|
|
7
|
519
|
April 29, 2025
|
|
HSA Industry Training Workshop 2024 - Management of Nitrosamine Impurities in Therapeutic Products
|
|
2
|
235
|
April 29, 2025
|
|
N-nitroso-deucravacitinib
|
|
9
|
306
|
April 29, 2025
|
|
Unknown Impurity of Sertraline - Formamide?
|
|
13
|
400
|
April 28, 2025
|
|
Testing and controls for nitrosamines for components of container closure systems
|
|
17
|
1784
|
April 25, 2025
|
|
Novartis pauses some trials of cancer drug Kisqali to fix manufacturing
|
|
15
|
2306
|
April 25, 2025
|
|
Looking for insights on N-nitroso-sertraline analysis by LC-MS
|
|
9
|
455
|
April 24, 2025
|
|
Can we bypass confirmatory testing of DP based on Theoretical Calc. of NDSRI's
|
|
9
|
1371
|
April 24, 2025
|
|
🕵🏻 OTC Market Withdrawal of Diphenhydramine
|
|
0
|
319
|
April 24, 2025
|
|
Visualization of Categorized Compounds by CPCA
|
|
67
|
8533
|
April 24, 2025
|
|
Nitrosamines in Elastomers?
|
|
0
|
126
|
April 23, 2025
|
|
The NEW Analytical Hub -How, Why, Who?
|
|
4
|
396
|
May 28, 2025
|
|
FDA Generic Drugs Forum - Bioequivalence Approaches
|
|
2
|
573
|
April 22, 2025
|
|
Nitrosamines: Mass Spectrometry-Based Analytical Procedures Criterias
|
|
6
|
3364
|
April 22, 2025
|
|
Industrial Case Studies Demonstrating Applicability of ICH M7Control Options 3 and 4 for Nitrosamine Control -Pub
|
|
4
|
594
|
April 22, 2025
|
|
N-nitroso-esmolol
|
|
0
|
97
|
April 22, 2025
|